Linked Life Data

12398962

Source:http://linkedlifedata.com/resource/pubmed/id/12398962

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
9
pubmed:dateCreated
2002-10-25
pubmed:abstractText
Concomitant use of nonsteroidal anti-inflammatory drugs (NSAIDs), including the cyclooxygenase-2 (COX-2) specific inhibitors, with antihypertensive medication is common practice for many patients with arthritis. This study evaluated the effects of celecoxib 200 mg/day and rofecoxib 25 mg/day on blood pressure (BP) and edema in a 6-week, randomized, parallel-group, double-blind study in patients > or =65 years of age with osteoarthritis who were treated with fixed antihypertensive regimens. One thousand ninety-two patients received study medication (celecoxib, n = 549; rofecoxib, n = 543). Significantly more patients in the rofecoxib group compared with the celecoxib group developed increased systolic BP (change >20 mm Hg plus absolute value > or =140 mm Hg) at any time point (14.9% vs 6.9%, p <0.01). Rofecoxib caused the greatest increase in systolic BP in patients receiving angiotensin-converting enzyme inhibitors or beta blockers, whereas those on calcium channel antagonists or diuretic monotherapy receiving either celecoxib or rofecoxib showed no significant increases in BP. Clinically significant new-onset or worsening edema associated with weight gain developed in a greater percentage of patients in the rofecoxib group (7.7%) compared with the celecoxib group (4.7%) (p <0.05). Thus, in patients with controlled hypertension on a fixed antihypertensive regimen, careful monitoring of BP is warranted after the initiation of celecoxib or rofecoxib therapy.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0002-9149
pubmed:author
pubmed:issnType
Print
pubmed:day
1
pubmed:volume
90
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
959-63
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed-meshheading:12398962-Age Factors, pubmed-meshheading:12398962-Aged, pubmed-meshheading:12398962-Anti-Inflammatory Agents, Non-Steroidal, pubmed-meshheading:12398962-Antihypertensive Agents, pubmed-meshheading:12398962-Blood Pressure, pubmed-meshheading:12398962-Cyclooxygenase Inhibitors, pubmed-meshheading:12398962-Double-Blind Method, pubmed-meshheading:12398962-Drug Evaluation, pubmed-meshheading:12398962-Edema, pubmed-meshheading:12398962-Female, pubmed-meshheading:12398962-Heart Failure, pubmed-meshheading:12398962-Humans, pubmed-meshheading:12398962-Hypertension, pubmed-meshheading:12398962-Lactones, pubmed-meshheading:12398962-Male, pubmed-meshheading:12398962-North America, pubmed-meshheading:12398962-Osteoarthritis, pubmed-meshheading:12398962-Pyrazoles, pubmed-meshheading:12398962-Sulfonamides, pubmed-meshheading:12398962-Sulfones, pubmed-meshheading:12398962-Systole, pubmed-meshheading:12398962-Treatment Outcome, pubmed-meshheading:12398962-Weight Gain
pubmed:year
2002
pubmed:articleTitle
Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis.
pubmed:affiliation
Universal Clinical Research Center, Inc., and The Johns Hopkins University School of Medicine, Baltimore, Maryland 21030-1603, USA. huntvalley@col.com
pubmed:publicationType
Journal Article, Clinical Trial, Comparative Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't, Multicenter Study